Ipsen: all 356 studies

Page 3 of 4. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.WithdrawnNCT04632199Phase 1
• Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.WithdrawnNCT04609800
• A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal SpasticityCompletedNCT04604379
• Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.CompletedNCT04593420
• Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
• Odevixibat for the Treatment of Progressive Familial Intrahepatic CholestasisNo longer availableNCT04483531
• Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinACompletedNCT04446702
• A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.CompletedNCT04396704
• Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsCompletedNCT04353765
• Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type ACompletedNCT04340336
• Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedNCT04336722Phase 3
• First-in-Human Study of ICT01 in Patients With Advanced CancerActive, not recruitingNCT04243499Phase 1/2
• A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionTerminatedNCT04241835Phase 1
• Tazemetostat Expanded Access Program for Adults With Epithelioid SarcomaNo longer availableNCT04225429
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
• Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaTerminatedNCT04204941Phase 1
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
• Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT04106349
• Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life CohortCompletedNCT04050527
• Study to Predict Lanreotide-induced Disease Activity Normalization in AcromegalyWithdrawnNCT04003519
• Spasticity and Treatment Satisfaction Among Stroke SurvivorsCompletedNCT03995524
• Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.TerminatedNCT03947762
• Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical PracticeWithdrawnNCT03895463
• Tazemetostat Expanded Access Program for Adults With Solid TumorsNo longer availableNCT03874455
• Validation of Patient Reported Outcome Measures for Use in Hallux ValgusCompletedNCT03846687
• Epithelioid Sarcoma Natural History StudyCompletedNCT03837678
• Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsCompletedNCT03776123
• Validation of Patient Reported Outcome Measures for Use in VulvodyniaCompletedNCT03770169
• Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.CompletedNCT03744585
• Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCCompletedNCT03699579
• A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKCompletedNCT03696407
• Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)CompletedNCT03689673
• KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownNCT03669965Phase 2
• Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingNCT03647878
• Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled ConditionsCompletedNCT03608319Phase 1
• Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital EndometriosisCompletedNCT03586063
• Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing ColonoscopyCompletedNCT03562884Phase 3
• Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide AutogelCompletedNCT03562091
• Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyCompletedNCT03516110
• Validation of the Spasticity Related Quality of Life QuestionnaireCompletedNCT03442660Not applicable
• Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaCompletedNCT03419572
• Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainCompletedNCT03220087
• Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine TumorsCompletedNCT03112694
• An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy SubjectsCompletedNCT03082937Phase 1
• Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb SpasticityCompletedNCT03017729
• Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)CompletedNCT03017690
• To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsCompletedNCT03017313
• Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384CompletedNCT02963077Phase 1
• A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2
• Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine TumoursCompletedNCT02853422
• Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerCompletedNCT02853409
• Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic SubjectsCompletedNCT02807233
• A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine TumoursTerminatedNCT02788578
• Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursCompletedNCT02788565
• Community-based Neuroendocrine Tumor (NET) Research StudyCompletedNCT02730104
• Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mgTerminatedNCT02698384
• A4250, an IBAT Inhibitor in Pediatric CholestasisCompletedNCT02630875Phase 2
• Eziclen Drug Utilisation in Real Life SettingCompletedNCT02630680
• Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsCompletedNCT02630654
• Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.CompletedNCT02630641
• Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesCompletedNCT02542501
• Validation Study of the SAGIT® Instrument in AcromegalyCompletedNCT02539927
• Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life PracticeCompletedNCT02454803
• Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After StrokeCompletedNCT02444494
• Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.CompletedNCT02396966
• Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic PatientsCompletedNCT02390206
• Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post StrokeCompletedNCT02384330
• Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®CompletedNCT02353897
• A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT02322255
• EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive DisordersCompletedNCT02321475
• The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or OverCompletedNCT02321449
• ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb SpasticityCompletedNCT02275312
• Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerCompletedNCT02238366
• SAGIT for Classification of Patients With Acromegaly in Clinical PracticeCompletedNCT02231593
• A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL GeneCompletedNCT02141828Phase 1
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaCompletedNCT02110355Phase 1
• Double-blind, Randomised Study of A3384 in BAM/BADCompletedNCT02078856Phase 2
• RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following StrokeCompletedNCT02020980
• Predictive Factors StudyTerminatedNCT02020499
• A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedNCT02016729Phase 1
• Description of Sign-and-symptom Associations at Acromegaly Diagnosis.CompletedNCT02012127
• Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical PracticeCompletedNCT02012036
• A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 MonthsCompletedNCT01942369
• BN83495 Phase I in Post-menopausal WomenCompletedNCT01840488Phase 1
• Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)CompletedNCT01840475
• Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]CompletedNCT01840462
• Somatuline Predictive Factors in Acromegaly and NETCompletedNCT01840449
• Phase IV-Cervical Dystonia-INTEREST IN CD2CompletedNCT01753349
• A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedNCT01723020Phase 1
• A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingCompletedNCT01684150Phase 1
• IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish PopulationTerminatedNCT01676090
• Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.TerminatedNCT01562522Phase 2
• Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateCompletedNCT01560858
• One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With MacroadenomaCompletedNCT01471405
• Adult Subjects Suffering From Lower Limb Spasticity Following StrokeCompletedNCT01444794
• Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)WithdrawnNCT01438801Phase 4
• BN80927 in Patients With Advanced Malignant Solid TumorsCompletedNCT01435096Phase 1
• A Long-term Observational Study Cohort in Patients With Advanced Prostate CancerCompletedNCT01383863

← Ipsen overview and focus areas